お知らせ • Mar 04
Bright Minds Biosciences Inc. Expands Scientific Advisory Board
Bright Minds Biosciences Inc. announced the expansion of its Scientific Advisory Board (SAB) to include five distinguished experts in epilepsy research: Dennis Dlugos, MD, MSCE, Jacqueline French, MD, Terrence O'Brien, MD, Jo Sourbron, MD, PhD, MPharm, Joseph Sullivan, MD. Dennis J. Dlugos, MD, MSCE, is Professor of Neurology and Pediatrics at the University of Pennsylvania; and Director, Pediatric Epilepsy Program at Children’s Hospital of Philadelphia (CHOP). Dr. Dlugos currently serves as a Vice-President of the Epilepsy Study Consortium, Incorporated (ESCI). As Vice-President, he coordinates reviews and adjudications for pediatric epilepsy trials and participated in discussions with FDA regarding extrapolation of efficacy for focal-onset seizures to one-month to age, and the validity of Developmental and Epileptic Encephalopathy broadly (DEE Other) as a clinical indication for pivotal trials and FDA labelling. He received his MD from Columbia University College of Physicians and Surgeons, New York. He completed his internship in Pediatrics at the National Naval Medical Center, Bethesda, Maryland; residency in Neurology-Child Neurology at the University of Pennsylvania/CHOP; and Epilepsy fellowship at CHOP. Articles authored or co-authored by Dr. Dlugos have been published in Neurology, Annals of Neurology, Lancet Neurology, Epilepsia,Lancet, Nature, the New England Journal of Medicine, and other journals. Jacqueline French, MD, is a professor of Neurology in the Comprehensive Epilepsy Center at NYU Grossman School of Medicine and Founder/Director of the Epilepsy Study Consortium, an academic group that has performed a number of early phase epilepsy trials. Dr. French trained in Neurology at Mount Sinai Hospital in New York and did her fellowship at Mount Sinai hospital and Yale University. Dr. French serves as the Medical Director of the Epilepsy Foundation. She is the past president of the American Epilepsy Society. She has authored over 300 articles and chapters, and lectures internationally on use of antiseizure medicines. Terence J. O’Brien, MD, is Chair of Medicine (Neurology) and Head, The School of Translational Medicine, Monash University and Program Director, Alfred Brain and Deputy Director of Research, Alfred Health. He is a specialist in neurology and clinical pharmacology, with particular expertise in epilepsy and neurodegenerative diseases, pre-clinical and clinical trials, and in-vivo imaging in animal models and humans. He has published >850 peer-reviewed original papers which have been highly cited (>42,000 times GS). He has been a PI on >200 clinical trials, including 8 that have been translated from his basic discovery research program. He has received 18 research awards from national and international scientific bodies. Dr. Jo Sourbron, MD, PhD, MPharm, is a physician scientist with a clinical practice at the University Hospitals of Ghent (UZ Ghent, Belgium) and a postdoctoral researcher at the University of Leuven (UZ/KU Leuven, Belgium). Dr. Sourbron has a special interest in genetic forms of epilepsy and clinical trials for drug-resistant forms of epilepsy. He has been a preclinical researcher for over a decade, focused on finding novel serotonergic (5-HT) compounds for drug-resistant epilepsies. For the past five years, he has been particularly involved in research involving epilepsy with eyelid myoclonia (EEM) with prominent photic induction (Sunflower syndrome). Concomitantly, he was involved in the pilot clinical trial of fenfluramine in Sunflower syndrome patients. Finally, he participated in several other clinical trials for drug-resistant epilepsies, such as cannabidiol in the treatment of drug-resistant epileptic disorders . Joseph Sullivan, MD, is a professor of neurology and pediatrics at the University of California, San Francisco (UCSF) and director of the UCSF Pediatric Epilepsy Center of Excellence at Benioff Children’s Hospital. He has served as principal investigator for numerous clinical trials in pediatric epilepsy and has a particular interest in Dravet syndrome and PCDH19 related epilepsy. He completed a pediatric residency at the Ann & Robert H. Lurie Children’s Memorial Hospital of Northwestern University in Chicago, where he spent an additional year as pediatric chief resident. He then completed his neurology, child neurology and epilepsy training at the Hospital of the University of Pennsylvania and at The Children’s Hospital of Philadelphia, both in Philadelphia, before taking his first faculty position at UCSF in 2007. He currently serves on the Board of Directors and medical advisory board for the Dravet Syndrome Foundation and is chair of the PCDH19 Alliance scientific advisory board. Drs. Dlugos, French, O'Brien, Sourbron, and Sullivan join the Company’s current SAB members, Michael P. Bogenschutz, MD, Robert C. Malenka, MD, PhD, Herbert Y. Meltzer, MD, and Dr. Peter Hendricks, PhD.